Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 128,770 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 128,770 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $0.39, for a total value of $50,220.30. Following the sale, the insider owned 341,353 shares of the company’s stock, valued at approximately $133,127.67. This represents a 27.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $55,361.25.
• On Friday, June 12th, Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total value of $68,176.40.
• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $99,751.14.
• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Trading Down 7.4%

Shares of HOWL opened at $0.36 on Wednesday. Werewolf Therapeutics, Inc. has a 12 month low of $0.36 and a 12 month high of $2.38. The stock has a fifty day moving average price of $0.63 and a 200-day moving average price of $0.70. The firm has a market cap of $17.50 million, a PE ratio of -0.29 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, research analysts forecast that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth about $409,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Werewolf Therapeutics during the 3rd quarter worth about $304,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on HOWL shares. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.